• John G. Csernansky

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 120)

Table of contents

  1. Front Matter
    Pages I-XXV
  2. Susan A. Minchin, John G. Csernansky
    Pages 1-27
  3. Deborah Hartman, Frederick Monsma, Olivier Civelli
    Pages 43-75
  4. S. Hossein Fatemi, Herbert Y. Meltzer, Bryan L. Roth
    Pages 77-115
  5. Patricio O‚Donnell, Anthony A. Grace
    Pages 163-202
  6. Mark E. Bardgett, John G. Csernansky
    Pages 267-288
  7. N. R. Swerdlow, D. L. Braff, V. P. Bakshi, M. A. Geyer
    Pages 289-312
  8. Julia Golier, Michael Davidson
    Pages 313-331
  9. Herbert Y. Meltzer, Rakesh Ranjan
    Pages 333-357
  10. Linda Peacock, Jes Gerlach
    Pages 359-388
  11. Amy R. Koreen, Brian Sheitman, Jeffrey Lieberman
    Pages 389-444
  12. William O. Faustman, Anne L. Hoff
    Pages 445-477
  13. Edward S. Brodkin, Christopher J. McDougle, James F. Leckman
    Pages 479-504
  14. Bruce G. Pollock, Benoit H. Mulsant
    Pages 505-529
  15. Back Matter
    Pages 531-541

About this book


Antipsychotic drugs were first discovered in 1953, and not since the late 1970s has the Handbook of Experimental Pharmacology taken up this topic. A new treatment of this topic would be due under any circumstances; however, this is now particularly true, since remarkable progress has been made on several fronts in furthering our understanding of the mechanisms of antipsychotic drug action. First, we have learned that schizophrenia is an illness with particu­ lar neuroanatomical abnormalities, many of which suggest that the illness is caused by errors in neurodevelopment. These findings have helped to form a context for understanding neurochemical aberrations in the illness and suggest new approaches for pharmacological treatment. Propelled forward by rapid advances in neurochemical anatomy, current pathophysiological hypotheses of schizophrenia and antipsychotic drug action have taken on the appearance of complex electrical circuit diagrams. Second, molecular biology studies have now revealed that there is a multiplicity of dopamine receptors (i. e. , D , DZshort' j DZlong, D , D , and D ), some of which may become entirely new targets for 3 4 s antipsychotic drug action. Ironically, the development of drugs that are selec­ tive for these receptors and that can be used to investigate their function lags behind; yet the discovery of these new receptors offers unparalleled opportu­ nities for developing drugs with improved efficacy and fewer side effects.


Neuroleptika Parkinson anatomy attention depression dopamine drug neurochemistry neurophysiology pharmacodynamics pharmacokinetics pharmacology physiology schizophrenia serotonin

Editors and affiliations

  • John G. Csernansky
    • 1
  1. 1.Department of PsychiatryWashington University, School of MedicineSt. LouisUSA

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1996
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-64653-9
  • Online ISBN 978-3-642-61007-3
  • Series Print ISSN 0171-2004
  • Series Online ISSN 1865-0325
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods